Which antibiotic class provides strong anti-pseudomonal coverage and is commonly used for Pseudomonas infections?

Which antibiotic class provides strong anti-pseudomonal coverage and is commonly used for Pseudomonas infections?

• A. Anti-pseudomonal beta-lactams
• B. Macrolides
• C. Fluoroquinolones
• D. Glycopeptides

Answer: (A)

Strong anti-pseudomonal coverage is provided by anti-pseudomonal beta-lactams. These antibiotics are specifically active against Pseudomonas aeruginosa and are commonly used as first-line or empiric therapy for suspected or confirmed Pseudomonas infections because they reliably disrupt bacterial cell wall synthesis and are effective against many strains, including those with broader resistance. This class includes drugs like piperacillin-tazobactam, ceftazidime, cefepime, and the carbapenems (imipenem, meropenem, doripenem), as well as aztreonam in certain cases. They are favored in serious infections due to their broad activity and the ability to combine with beta-lactamase inhibitors to overcome resistance. Macrolides generally have poor activity against Pseudomonas and are not relied upon for Pseudomonas infections. Glycopeptides target mostly Gram-positive organisms and do not cover Pseudomonas, a Gram-negative rod. Fluoroquinolones can cover Pseudomonas, but they are not the standard class chosen for robust, broad anti-pseudomonal coverage in many settings, especially in severe infections where beta-lactams remain the cornerstone.

Strong anti-pseudomonal coverage is provided by anti-pseudomonal beta-lactams. These antibiotics are specifically active against Pseudomonas aeruginosa and are commonly used as first-line or empiric therapy for suspected or confirmed Pseudomonas infections because they reliably disrupt bacterial cell wall synthesis and are effective against many strains, including those with broader resistance. This class includes drugs like piperacillin-tazobactam, ceftazidime, cefepime, and the carbapenems (imipenem, meropenem, doripenem), as well as aztreonam in certain cases. They are favored in serious infections due to their broad activity and the ability to combine with beta-lactamase inhibitors to overcome resistance.

Macrolides generally have poor activity against Pseudomonas and are not relied upon for Pseudomonas infections. Glycopeptides target mostly Gram-positive organisms and do not cover Pseudomonas, a Gram-negative rod. Fluoroquinolones can cover Pseudomonas, but they are not the standard class chosen for robust, broad anti-pseudomonal coverage in many settings, especially in severe infections where beta-lactams remain the cornerstone.